Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 30/08/19941 min de lecture
Determination of Regulatory Review Period for Purposes of Patent Extension; RisperdalRegister
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) has determined the regulatory review period for Risperdal and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
Langue originale de la source: Federal Register — Health and Human ServicesOuvrir le communiqué original →